Target median: 16.25 +282%
Target mean: 16.625 +291%
Low: 15
High: 19
Recommendation: strong_buy ■ (mean: 1.25)
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.
[Traduction indisponible: No module named 'googletrans']
Microbiome.
Target median: 16.25
Target mean: 16.625
Low: 15
High: 19
Recommendation: strong_buy (mean: 1.25)